Name: Anti-SMAD4 antibody
Price: 332.00 USD

Overview
- Signaling from the ligand‐activated membrane receptor serine/threonine kinases to nuclear targets is mediated by a set of evolutionarily conserved proteins known as DPC4. Upon ligand binding, the receptors of the TGF‐β family phosphorylate SMAD proteins (SMAD1 and SMAD2). These proteins then move into the nucleus, where they activate transcription. To carry out this function, the receptor activated SMAD1 and 2 require association with the product of deleted in pancreatic carcinoma, locus 4 (DPC4), also known as SMAD4. SMAD4/DPC4 is also implicated as a tumor suppressor, since it is inactivated in more than half of pancreatic carcinomas and to a lesser extent in a variety of other cancers. The lack of SMAD4 expression is present in approximately 80% of cases of pancreatic adenocarcinoma, but rarely in endometrial (0%), colorectal (0%), ovarian (3%), lung (0%), breast (2%) adenocarcinomas, and malignant melanoma (4%). SMAD4 is an important marker for confirming a diagnosis of pancreatic adenocarcinoma.
  
  Please contact us at for specific academic pricing.
Properties
- Host
  
  mouse
  
  Antibody Type
  
  monoclonal
  
  Isotype
  
  IgG1 kappa
  
  Reactivity
  
  human
  
  Clone
  
  B‐8
  
  Immunogen
  
  Amino acid 1‐552 representing full length Smad4 of human origin.
  
  Conjugate
  
  Unconjugated
  
  Formulation
  
  Purified antibody diluted in Tris‐HCI buffer containing stabilizing protein and <0.1% sodium azide.
  
  Storage
  
  Store at 2-8°C for up to 1 year
  
  Regulatory Status
  
  RUO
  
  Antigen
  
  Mothers Against Decapentaplegic Homolog 4; Mad Homolog 4; Mothers Against Dpp Homolog 4; Deletion Target In Pancreatic Carcinoma 4; Smad Family Member 4; Smad 4; Smad4; Hsmad4 (Gene ID:4089; UniProt:Q13485)
  
  * For research use only